Inhibikase Therapeutics, Inc.
IKT
$2.41
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.82% | 8.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.57% | 217.70% | |||
| Operating Income | -15.57% | -217.70% | |||
| Income Before Tax | -19.60% | -28.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.60% | -28.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.60% | -28.63% | |||
| EBIT | -15.57% | -217.70% | |||
| EBITDA | -15.58% | -217.43% | |||
| EPS Basic | -17.98% | 7.67% | |||
| Normalized Basic EPS | -15.30% | -156.54% | |||
| EPS Diluted | -17.98% | 7.67% | |||
| Normalized Diluted EPS | -15.30% | -156.54% | |||
| Average Basic Shares Outstanding | 1.31% | 39.36% | |||
| Average Diluted Shares Outstanding | 1.31% | 39.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||